Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
5.6
-23.77%
60%
—
9x
80%
—
5 Years
Score5.6
Net Growth-23.77%
Net Trend60%
Net Income Consistency—
Rev Growth9x
Rev Trend80%
Revenue Consistency—
BridgeBio Pharma Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 8M to $ 502M and net income went from -$ 448M to -$ 729M. Revenue increased in 4 of those 5 years; net income in 3.
BridgeBio Pharma Inc currently holds a 5-year HDB Score of 5.6 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 83.84 | — |
1 Year2025-08-12 | $ 49.09 | 70.79% |
5 Years2021-08-12 | $ 50.84 | 64.91% |
All Time2019-06-27 | $ 27.55 | 204.32% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2019-06-27 |
|---|---|---|---|---|
| Price | $ 83.84 | $ 49.09 | $ 50.84 | $ 27.55 |
| Return | — | 70.79% | 64.91% | 204.32% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 677M | -$ 696M | $ 720M |
| 2025 | $ 502M | -$ 729M | $ 587M |
| 2024 | $ 221M | -$ 535M | $ 681M |
| 2023 | $ 9M | -$ 643M | $ 434M |
| 2022 | $ 77M | -$ 481M | $ 471M |
| 2021 | $ 69M | -$ 562M | $ 836M |
| 2020 | $ 8M | -$ 448M | $ 607M |
| IPO2019 | $ 40M | -$ 260M | $ 545M |
Explore beyond BBIO
You're looking at BridgeBio Pharma Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
